Simplex Trading
VRDN icon

Simplex Trading’s Viridian Therapeutics VRDN Stock Holding History

Simplex Trading’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.96K Buy
+270
New +$4.35K ﹤0.01% 8181
2025
Q4 		– Sell
-2,756
Closed -$75.6K – 10212
2025
Q3 		$59K Buy
+2,756
New +$49.7K ﹤0.01% 6297
2025
Q2 		– Sell
-8,412
Closed -$114K – 9837
2025
Q1 		$113K Buy
+8,412
New +$143K ﹤0.01% 4940
2024
Q4 		– Sell
-911
Closed -$19.8K – 9739
2024
Q3 		$20K Buy
+911
New +$14.9K ﹤0.01% 6690
2024
Q1 		– Sell
-2,856
Closed -$55.4K – 10006
2023
Q4 		$62K Buy
2,856
+1,128
+65% +$17.8K ﹤0.01% 5885
2023
Q3 		$26K Sell
1,728
-21,652
-93% -$413K ﹤0.01% 6400
2023
Q2 		$556K Buy
23,380
+22,821
+4,082% +$585K ﹤0.01% 3198
2023
Q1 		$14K Sell
559
-4,502
-89% -$144K ﹤0.01% 7270
2022
Q4 		$147K Sell
5,061
-6,009
-54% -$138K ﹤0.01% 4615
2022
Q3 		$227K Buy
11,070
+9,831
+793% +$177K ﹤0.01% 4449
2022
Q2 		$14K Buy
+1,239
New +$16.7K ﹤0.01% 7987

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Simplex Trading's VRDN Position: Q2 2026 in Review

Simplex Trading opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 270 shares worth $4.96K. The stake represents ﹤0.01% of the portfolio and ranks #8181 among its holdings. This is a return to the name: Simplex Trading previously reported a position in VRDN as recently as Q3 2025.

Simplex Trading first reported a position in VRDN in Q2 2022 and has held it in 11 quarters since. The position peaked at $556K in Q2 2023. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Simplex Trading held 270 shares of Viridian Therapeutics worth $4.96K as of Q2 2026.
  • Viridian Therapeutics was a new Simplex Trading position in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #8181 holding.
  • Simplex Trading first reported a position in Viridian Therapeutics in Q2 2022 and has held it in 11 quarters since.
  • Simplex Trading's Viridian Therapeutics position peaked at $556K in Q2 2023.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.